Navigation Links
Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:6/4/2010

"We have the potential to individualize the treatment of early-stage renal cell carcinoma by assessing the risk of recurrence more accurately," said Isan Chen, M.D., Vice President - Genitourinary Tumor Strategy Team Leader, Pfizer Oncology Business Unit. "With a growing portfolio of kidney cancer therapies, Pfizer is committed to advancing the science and management of this disease.  Together with Genomic Health we intend to continue to define the clinical strategy and next steps for our work in renal cell carcinoma."

(i) Dr. Rini is also a member of the Pfizer scientific advisory board.  

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. As of March 31, 2010, more than 10,000 physicians in over 55 countries had ordered more than 148,000 Oncotype DX tests. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit '/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
2. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
3. Genomic Health to Announce First Quarter 2010 Financial Results and Host Conference Call on Wednesday, May 5, 2010
4. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
5. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
6. Transgenomic Reports Fourth Quarter Financial Results
7. AutoGenomics Announces the Launch of a Novel Test for B-RAF Mutations
8. NeoGenomics Schedules Its Q4 and Full Year 2009 Earnings Release for February 25, 2010
9. AutoGenomics Receives ISO Certification
10. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
11. Genomic Health Announces Year-End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- Today leading ... all new data ranking Pharmaceutical web sites for usability, ... Sciences, User Experience Cloud platform, which compares how people ... on the web. The top three performers ... convert people overall. The bottom performers have usability problems, ...
(Date:6/19/2013)... 19, 2013 /PRNewswire-iReach/ -- In its first ... pharmaceutical company dedicated to advancing development of ... sustained release drug therapies in patient disease ... announced the acquisition of Enzon Pharmaceutical,s PEGylation ... associated product pipeline. Acquisition of this technology ...
(Date:6/19/2013)... 19, 2013  Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... number one overall pharmacy equipment vendor in the ... a leading independent healthcare research firm, compared the ... its annual rankings. Omnicell also received the prestigious ...
Breaking Medicine Technology:Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4
...   Unigene Laboratories, Inc. (OTCBB: UGNE), ... of peptide-based therapeutics, announced that Ashleigh Palmer, President and ... the Biotech Showcase™ 2012 in San Francisco, CA on ... p.m. ET).  Mr. Palmer,s presentation will include an overview of ...
... Md., Jan. 4, 2012 /PRNewswire-iReach/ -- ... pharmaceutical company focused exclusively in the HIV-1 therapeutic ... to provide medicinal chemistry services to support DFH ... maturation inhibitor drugs. Maturation inhibitors are a novel ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 3
(Date:6/19/2013)... 2013 McGuff Pharmaceuticals, Inc. ... Drug Application (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, ... Squibb’s drug fomerly known as Delalutin™. We are ... the anticipated approval and market introduction dates for McGuff’s ... status of our pending ANDA, to date, McGuff has ...
(Date:6/19/2013)... Calculating insurance rates is a complex process that ... and of course their own company policies. This process ... from company to company, and why by shopping around for ... often save, as car insurance can be a hefty expense ... the top factors that determine their car insurance premiums. ...
(Date:6/19/2013)... June 19, 2013 Sudden cardiac arrest can ... sets in an average of 5 minutes after cardiac arrest, ... 11 minutes. This means that death is highly probable if ... readily available for use. In response to this dire reality, ... to Save Lives Act (H.R. 2308) which would provide support ...
(Date:6/19/2013)... June 19, 2013 Anant Goel, CEO at ... changing rapidly. The first industrial revolution began in Britain in ... industry… when the factory was born. The second industrial revolution ... the moving assembly line and ushered in the age of ... the 21st century. Manufacturing is going digital and this could ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Indosoft ... Center ACD for Asterisk, announced today the ... 5.7. This enhancement offers improved options for extracting, ... dashboards for effective contact center management. , Large ... real-time captured as it happens from the call ...
Breaking Medicine News(10 mins):Health News:Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP 2Health News:icandrive.ca Provides Tips to Understand the Top Factors That Affect Car Insurance Premiums 2Health News:icandrive.ca Provides Tips to Understand the Top Factors That Affect Car Insurance Premiums 3Health News:AED.com Supports Automated External Defibrillator (AED) Legislation in Schools in US and UK 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 3Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 4Health News:Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity 2
... for foreign markets and plans,Canadian rollout, ... (OTC,Bulletin Board: UKMA), a lifestyle multimedia and ... personal development, announced today that,its exclusive international ... Xflowsion DVD series at the Electronic,Retailer,s Association ...
... Determinations, WASHINGTON, Oct. 28 National ... Administration,s,new "Compassionate Allowances Process" for disability determinations, ... Before announcing this,proposal, Social Security held public ... information from experts. NPAF, in collaboration with ...
... could reduce the cost and time required for cancer ... 28 online issue of the Journal of the ... a multistep process that involves in vitro tests, animal ... Inadequately designed rodent studies have led to missteps and ...
... DURHAM, N.C. -- Popular cholesterol-busting drugs -- statins -- appear ... according to researchers in the Duke Prostate Center and the ... prevent prostate cancer growth or just mask it is not ... statins were less likely to develop advanced forms of prostate ...
... become a billion-dollar substitute for flying business people ... to make sound judgments about speakers being viewed ... in a journal of the Institute for Operations ... in the Field: A Heuristic Processing Model" is ...
... because it may worsen another is a treatment trade-off ... rather take part in, researchers at Yale School of ... Journal of the American Geriatrics Society . , ... least two chronic conditions, and 24 percent have four ...
Cached Medicine News:Health News:uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series 2Health News:National Patient Advocate Foundation (NPAF) Commends SSA's New 'Compassionate Allowances Process' 2Health News:Cholesterol-lowering drugs may also lower PSA, but whether they cut cancer risk is still not known 2Health News:Videoconferencing more confusing for decision-makers than face-to-face meetings 2Health News:Elderly fare better when included in decisions on treatment trade-offs 2
Fenestrated 14 mm blades. Wide extension of blade for protection of lids. Self-locking mechanism. Dull finish....
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Infant model. Blades: 7 mm. Solid blades with locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: